Diaphragm Thickness by Ultrasonography in Neurological Disorders

Status Completed

Clinical Trial Summary

participants will be allocated into three groups, acute neuropathy (Guillain Barre Syndrome) group, neuromuscular junction disorder(myasthenia gravis ) group, and control group(people with neurological disorders not affecting the respiratory system.Ultrasonography is done on the diaphragm. The index test (ultrasound imaging of the diaphragm) is used. A high-resolution portable ultrasound machine is used, with a 7- to 13-MHz linear array transducer. Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration. objectives: primary outcome: to compare diaphragm thickness between the three examined groups. Secondary outcome: correlation between clinical scores and reference US values of diaphragm

Clinical Trial Description

after IRB (institutional research board ) approval, of the faculty of medicine, Mansoura University, Egypt, written informed consent from all participants will be taken. participants will be allocated into three groups, acute neuropathy (Guillain Barre Syndrome) group, neuromuscular junction disorder(myasthenia gravis ) group, and control group(people with neurological disorders not affecting the respiratory system. inclusion group: age more than 18, both sexes. exclusion criteria: cardiopulmonary disease, chest trauma, diaphragmatic injury, body mass index more than 30. Any participant who shows respiratory dysfunction on doing arterial blood gases and pulmonary function tests will not be enrolled in the study. methods: Ultrasonography is done on the diaphragm. The index test (ultrasound imaging of the diaphragm) is used. A high-resolution portable ultrasound machine is used, with a 7- to 13-MHz linear array transducer. Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration. objectives: primary outcome: to compare diaphragm thickness between the three examined groups. Secondary outcome: correlation between clinical scores and reference US values of diaphragm ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05324176
Study type	Interventional
Source	Mansoura University
Contact
Status	Completed
Phase	N/A
Start date	April 13, 2022
Completion date	May 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05039190` - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients	Phase 3
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT01727193` - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy	Phase 3
Completed	`NCT00285350` - Mycophenolate Mofetil in Myasthenia Gravis	Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed	`NCT05694234` - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting	`NCT04965987` - Oxaloacetate in Myasthenia Gravis	Phase 1
Not yet recruiting	`NCT05095103` - Immune Profiles in Myasthenia Gravis
Completed	`NCT02774239` - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)	Phase 3
Terminated	`NCT02102594` - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Phase 2
Completed	`NCT02066519` - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis	N/A
Completed	`NCT02118805` - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated	`NCT01828294` - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis	Phase 1
Terminated	`NCT00727194` - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT04590716` - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting	`NCT04837625` - Study of Myasthenic Crisis in China
Not yet recruiting	`NCT01469858` - Perception and Multisensory Integration in Neurological Patients Using fMRI	N/A
Completed	`NCT05408702` - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed	`NCT03205306` - Myasthenia Gravis and Psyche

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.